This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Radius Health Gestion

Gestion contrôle des critères 2/4

Informations clés

G. Martin

Directeur général

US$3.5m

Rémunération totale

Pourcentage du salaire du PDG	17.2%
Durée du mandat du directeur général	2.3yrs
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	6.8yrs

Mises à jour récentes de la gestion

Recent updates

Radius Recycling Stays In The Scrap Pile

Jul 16

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Jun 03

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

Aug 11

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Jan 01

Radius Health on-track for record quarterly revenue for TYMLOS-SC

Dec 15

Analyse de la rémunération des PDG

Comment la rémunération de G. Martin a-t-elle évolué par rapport aux bénéfices de Radius Health?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2022	n/a	n/a	-US$69m
Mar 31 2022	n/a	n/a	-US$73m
Dec 31 2021	US$3m	US$600k	-US$70m
Sep 30 2021	n/a	n/a	-US$76m
Jun 30 2021	n/a	n/a	-US$60m
Mar 31 2021	n/a	n/a	-US$87m
Dec 31 2020	US$12m	US$413k	-US$109m

Rémunération vs marché: G.'s total compensation ($USD3.49M) is above average for companies of similar size in the US market ($USD2.61M).

Rémunération et revenus: G.'s compensation has been consistent with company performance over the past year.

PDG

G. Martin (63 yo)

2.3yrs

Titularisation

US$3,493,881

Compensation

Mr. G. Kelly Martin has been Executive Chairman of Wren Therapeutics Ltd. since 2018. Mr. Martin serves as the Chief Executive Officer, President and Director at Radius Health, Inc. since April 28, 2020.H...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
G. Martin	CEO, President & Director	2.3yrs	US$3.49m	pas de données
Danielle Holtschlag	VP of Sales & Head of U.S. Sales Channels	less than a year	US$741.78k	pas de données
Chhaya Shah	Senior VP & Chief Business Officer	2.2yrs	US$1.22m	0.27% $ 1.3m
Stavros Manolagas	Founder & Member of the Scientific Advisory Board	no data	pas de données	pas de données
John Potts	Founder & Member of the Scientific Advisory Board	no data	pas de données	pas de données
Michael Rosenblatt	Founder	no data	pas de données	pas de données
John Katzenellenbogen	Founder & Member of the Scientific Advisory Board	no data	pas de données	pas de données
Mark Conley	VP, CFO	less than a year	pas de données	pas de données
Peter Schwartzman	Head of Corporate Finance	no data	pas de données	pas de données
Ethan Holdaway	Head of Investor Relations	less than a year	pas de données	pas de données
Kim Clarke	General Counsel	less than a year	pas de données	pas de données
Rohan Lathia	Head of Corporate & Business Development	less than a year	pas de données	pas de données

0.8yrs

Durée moyenne de l'emploi

61.5yo

Âge moyen

Gestion expérimentée: RDUS's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
G. Martin	CEO, President & Director	2.3yrs	US$3.49m	pas de données
Stavros Manolagas	Founder & Member of the Scientific Advisory Board	no data	pas de données	pas de données
John Potts	Founder & Member of the Scientific Advisory Board	no data	pas de données	pas de données
Michael Rosenblatt	Founder	no data	pas de données	pas de données
John Katzenellenbogen	Founder & Member of the Scientific Advisory Board	no data	pas de données	pas de données
Jean-Pierre Garnier	Independent Director	6.7yrs	US$544.81k	0.045% $ 215.1k
Sean Murphy	Independent Director	2yrs	US$534.84k	0.012% $ 55.5k
Willard Dere	Independent Director	7.8yrs	US$536.69k	0.037% $ 178.7k
Cecil Richard Lyttle	Chairman of Scientific Advisory Board	10.5yrs	US$30.00k	pas de données
Owen Hughes	Independent Chairman	9.3yrs	US$832.23k	0.034% $ 163.1k
Catherine Friedman	Independent Director	7yrs	US$556.41k	0.045% $ 215.1k
Gary Hattersley	Member of Scientific Advisory Board	3.8yrs	US$1.94m	pas de données

6.8yrs

Durée moyenne de l'emploi

68.5yo

Âge moyen

Conseil d'administration expérimenté: RDUS's board of directors are considered experienced (6.8 years average tenure).

This company listing is no longer active

Radius Health Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Radius Health, Inc., Annual General Meeting, Jul 08, 2022

Radius Health, Inc. Appoints Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors

Radius Health, Inc. Announces Board Changes

Radius Health, Inc. Hires Peter Been as Executive Director and Head of Clinical Development for the Abaloparatide Program

Radius Health, Inc. Announces Management Changes

Recent updates

Radius Recycling Stays In The Scrap Pile

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Radius to Be Delisted from the NASDAQ Global Market

Patient Square Capital, LP and Gurnet Point Capital Limited completed the acquisition of Radius Health, Inc. (NasdaqGM:RDUS) from Repertoire Partners LP, Velan Capital Investment Management LP and others.

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Velan-Repertoire to Withdraw Director Nominations due to Pending Sale of Radius Health

Radius Health, Inc. Announces First Patient Randomized in the Rad011 Pivotal Trial for Prader-Willi Syndrome

Price target increased to US$10.00

Patient Square Capital, LP and Gurnet Point Capital Limited entered into a definitive agreement to acquire Radius Health, Inc. (NasdaqGM:RDUS) for approximately $500 million.

Menarini Group and Radius Health Submit New Drug Application to the U.S. FDA for Elacestrant

Velan Capital Investment Responds to Radius Health’s Board

Now 24% undervalued after recent price drop

Radius Health, Inc., Annual General Meeting, Jul 08, 2022

Menarini Group and Radius Health, Inc. Present A Subgroup Analysis from the Elacestrant Pivotal Phase 3 EMERALD Clinical Trial At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Radius Health, Inc. Provides Update on Abaloparatide Transdermal System

Velan LP Provides Information to Shareholders of Radius Health Inc

Radius Health, Inc. Appoints Jennifer A. Jarrett and Susan Vissers Lisa to Board of Directors

Consensus forecasts updated

Radius Health, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Forecast breakeven date moved forward to 2022

Consensus forecasts updated

Radius Health, Inc. to Report Q1, 2022 Results on May 05, 2022

Consensus forecasts updated

Consensus forecasts updated

Velan Capital Engages in Discussions with Radius Health

Radius Health Files Supplemental New Drug Application with the Food and Drug Administration for TYMLOS in Men with Osteoporosis

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date moved forward to 2022

Reevaluating Radius Health

Forecast breakeven date pushed back to 2023

Radius Announces Update on TYMLOS® (abaloparatide) Label

Radius Health, Inc. Announces Results from the wearABLe Trial Evaluating Abaloparatide Transdermal System in Postmenopausal Women with Osteoporosis

Price target decreased to US$20.50

Forecast breakeven date pushed back to 2023

Third quarter 2021 earnings released: US$0.47 loss per share (vs US$0.14 loss in 3Q 2020)

Price target increased to US$23.86

CFO, VP, Treasurer, Principal Finance Officer & Principal Accounting Officer James Chopas has left the company

Price target decreased to US$22.29

Second quarter 2021 earnings released: US$0.35 loss per share (vs US$0.94 loss in 2Q 2020)

Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study

Consensus forecasts updated

Consensus forecasts updated

Radius Health, Inc. Reiterates Revenue Guidance for the Full Year of Fiscal 2021

First quarter 2021 earnings released: US$0.34 loss per share (vs US$0.81 loss in 1Q 2020)

Radius Health EPS misses by $0.02, misses on revenue

Consensus forecasts updated

Analysts update estimates

Full year 2020 earnings released: US$2.35 loss per share (vs US$2.89 loss in FY 2019)

Revenue beats expectations

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

Radius Health, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: US$22.94

Revisiting Radius Health

Price target raised to US$22.00

New 90-day high: US$21.60

Radius Health, Inc. Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada

Radius Health acquires global rights to RAD011 in Prader-Willi syndrome

Radius Health, Inc. Announces Board Changes

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

Radius Health, Inc. Hires Peter Been as Executive Director and Head of Clinical Development for the Abaloparatide Program

New 90-day high: US$18.54

Radius Health on-track for record quarterly revenue for TYMLOS-SC

New 90-day high: US$14.86

Revenue and earnings miss expectations

Third quarter 2020 earnings released: US$0.14 loss per share

New 90-day high: US$13.88

New 90-day low: US$10.80